Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exendin (9-39) for post-bariatric hypoglycemia
NCT02550145Phase 1Terminated
- Start
- Feb 2014
- Primary completion
- Dec 2016
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of exendin 9-39 in hypoglycemia. Primary endpoint: Plasma glucose area under the curve at 180 months. Started Feb 2014; status: terminated.
02
Drugs
exendin 9-39
03
Conditions
hypoglycemia
Beyond the preview
Go deeper on NCT02550145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02550145.